Duncan-Williams is out with its report today on ICU Medical ICUI, maintaining Buy.
In a note to clients, Duncan-Williams writes, "On April 14, 2011, ICUI announced it was awarded a 36-month contract with Premier Purchasing Partners, L.P., the group purchasing unit of Premier Inc., for its hemodynamic monitoring products, which are mostly used in the critical care setting. We are maintaining our BUY rating and our twelve month price target of $48.00. This represents approximately 20 times our current 2011 EPS estimate of $2.40."
Shares of ICUI closed Thursday at $44.79.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorPrice TargetAnalyst RatingsDuncan-WilliamsHealth CareHealth Care SuppliesICU Medical
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in